Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 213

1.

Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis.

Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH; Psoriasis Study Group., Durez P, Tak PP, Gomez-Reino JJ; Rheumatoid Arthritis Study Group., Foster CS, Kim RY, Samson CM, Falk NS, Chu DS, Callanan D, Nguyen QD; Uveitis Study Group., Rose K, Haider A, Di Padova F.

Sci Transl Med. 2010 Oct 6;2(52):52ra72. doi: 10.1126/scitranslmed.3001107.

2.

Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis.

Kirkham BW, Kavanaugh A, Reich K.

Immunology. 2014 Feb;141(2):133-42. doi: 10.1111/imm.12142. Review.

3.

Effect of IL-17A blockade with secukinumab in autoimmune diseases.

Patel DD, Lee DM, Kolbinger F, Antoni C.

Ann Rheum Dis. 2013 Apr;72 Suppl 2:ii116-23. doi: 10.1136/annrheumdis-2012-202371. Epub 2012 Dec 19. Review.

PMID:
23253932
4.

Synergistic effects of interleukin-1β and interleukin-17A antibodies on collagen-induced arthritis mouse model.

Zhang Y, Ren G, Guo M, Ye X, Zhao J, Xu L, Qi J, Kan F, Liu M, Li D.

Int Immunopharmacol. 2013 Feb;15(2):199-205. doi: 10.1016/j.intimp.2012.12.010. Epub 2012 Dec 29.

PMID:
23280345
5.

The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases.

Toussirot E.

Inflamm Allergy Drug Targets. 2012 Apr;11(2):159-68. Review.

PMID:
22280236
6.

Secukinumab (AIN457) for the treatment of psoriasis.

López-Ferrer A, Vilarrasa E, Puig L.

Expert Rev Clin Immunol. 2015;11(11):1177-88. doi: 10.1586/1744666X.2015.1095092. Epub 2015 Oct 1. Review.

PMID:
26428036
7.

Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis.

Chao CC, Chen SJ, Adamopoulos IE, Davis N, Hong K, Vu A, Kwan S, Fayadat-Dilman L, Asio A, Bowman EP.

Autoimmunity. 2011 May;44(3):243-52. doi: 10.3109/08916934.2010.517815. Epub 2010 Oct 7.

PMID:
20925596
8.

Secukinumab: first global approval.

Sanford M, McKeage K.

Drugs. 2015 Feb;75(3):329-38. doi: 10.1007/s40265-015-0359-0. Review.

PMID:
25648267
9.
10.

Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.

Spuls PI, Hooft L.

Br J Dermatol. 2012 Oct;167(4):710-3; discussion 714-5. doi: 10.1111/bjd.12025.

PMID:
23013312
11.

IL-17 targeted therapies for psoriasis.

Chiricozzi A, Krueger JG.

Expert Opin Investig Drugs. 2013 Aug;22(8):993-1005. doi: 10.1517/13543784.2013.806483. Epub 2013 Jun 3. Review.

PMID:
23731078
12.

Th17 cells and IL-17 a--focus on immunopathogenesis and immunotherapeutics.

van den Berg WB, McInnes IB.

Semin Arthritis Rheum. 2013 Oct;43(2):158-70. doi: 10.1016/j.semarthrit.2013.04.006. Review.

PMID:
24157091
13.

Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.

Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, Braun D, Banerjee S.

N Engl J Med. 2012 Mar 29;366(13):1190-9. doi: 10.1056/NEJMoa1109997.

14.

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.

Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK.

Clin Ther. 2003 Jun;25(6):1700-21.

PMID:
12860493
15.

HuMax-CD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris.

Skov L, Kragballe K, Zachariae C, Obitz ER, Holm EA, Jemec GB, Sølvsten H, Ibsen HH, Knudsen L, Jensen P, Petersen JH, Menné T, Baadsgaard O.

Arch Dermatol. 2003 Nov;139(11):1433-9.

PMID:
14623703
16.

Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.

Sofen H, Smith S, Matheson RT, Leonardi CL, Calderon C, Brodmerkel C, Li K, Campbell K, Marciniak SJ Jr, Wasfi Y, Wang Y, Szapary P, Krueger JG.

J Allergy Clin Immunol. 2014 Apr;133(4):1032-40. doi: 10.1016/j.jaci.2014.01.025.

17.

Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy.

Letko E, Yeh S, Foster CS, Pleyer U, Brigell M, Grosskreutz CL; AIN457A2208 Study Group..

Ophthalmology. 2015 May;122(5):939-48. doi: 10.1016/j.ophtha.2014.12.033. Epub 2015 Jan 29.

PMID:
25638011
18.

Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).

Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J.

Arthritis Rheum. 2005 Apr;52(4):1227-36. Erratum in: Arthritis Rheum. 2005 Sep;52(9):2951.

19.

Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.

Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, Cheung N, Williams B, Hazleman B, Price R, Yoshizaki K, Nishimoto N, Kishimoto T, Panayi GS.

Arthritis Rheum. 2002 Dec;46(12):3143-50.

20.

Interleukin 17A: toward a new understanding of psoriasis pathogenesis.

Lynde CW, Poulin Y, Vender R, Bourcier M, Khalil S.

J Am Acad Dermatol. 2014 Jul;71(1):141-50. doi: 10.1016/j.jaad.2013.12.036. Epub 2014 Mar 18. Review.

PMID:
24655820

Supplemental Content

Support Center